CPRX
Catalyst Pharmaceuticals, Inc.
Healthcare · Biotechnology
Undervalued·Quality 100·RSI 57·DCF +544%·Conviction 85
Investment Thesis — Catalyst Pharmaceuticals, Inc.
The market undervalues Catalyst Pharmaceuticals, pricing it as a mature, single-product pharma with limited growth. It fails to account for the durable growth potential of its rare disease franchise and the underappreciated optionality within its pipeline, particularly in neuromuscular disorders.
Catalysts
- Positive Phase 3 data for agamifampridine in new indications
- FDA approval for Firdapse label expansion (e.g., MuSK-MG)
- Stronger-than-expected Firdapse sales growth driven by increased penetration
Risk Factors
- Clinical trial failure for key pipeline candidates
- Unexpected generic competition or new entrants for Firdapse
- Regulatory delays or adverse decisions impacting existing or pipeline products
Key Debates
Fwd P/E re-rates above 20x by Q4 due to growth.
Gross margin holds above 80% through FY24.
Stock hits $33 analyst target within 9 months.